---
title: "Key 2025 Advances in Autologous Cellular Therapy for Melanoma and Solid Tumors"
id: "pubmed-42734903"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42734903"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42734903/"
doi: "10.1002/cncr.70612"
published_at: "2026-09-15T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Key 2025 Advances in Autologous Cellular Therapy for Melanoma and Solid Tumors
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42734903
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42734903/)
- **DOI:** [10.1002/cncr.70612](https://doi.org/10.1002%2Fcncr.70612)
- **Published At:** 2026-09-15T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- The review summarizes major 2025 advances in **autologous cellular therapy** for melanoma and other solid tumors, building on 2024 regulatory milestones. - **Lifileucel**, the first FDA-approved **tumor-infiltrating lymphocyte (TIL)** therapy for advanced melanoma, showed durable efficacy in a 5-year C-144-01 analysis with an objective response rate (ORR) of **31.4%** in a heavily pretreated population. - Real-world data on lifileucel indicate effectiveness and suggest higher ORR in some settings, likely due to earlier lines of therapy and patient selection differences. - A PRAME-targeted **TCR T-cell therapy** (anzu-cel/IMA203) produced promising phase 1 activity with an ORR of approximately **50%** in checkpoint inhibitor–refractory melanoma and manageable toxicity, supporting PRAME as a cross-tumor target. - Next-generation engineered **TIL** platforms aim to reduce dependence on high-dose IL-2; OBX-115, an IL-2–independent TIL engineered to express membrane-bound IL-15 regulated by acetazolamide, showed early phase 1 activity with an ORR of **67%** in initial data. - Gene-editing strategies, including CRISPR-mediated modifications and checkpoint disruption, are highlighted as part of a shift toward programmable, self-sustaining cellular therapies. - Personalized neoantigen-based approaches—both adoptive T-cell platforms and mRNA vaccines—advanced with early clinical validation showing immune activation and improved recurrence-free survival in melanoma. - Afamitresgene autoleucel (**afami-cel**), a MAGE-A4–directed **TCR-T** therapy, demonstrated durable efficacy in synovial sarcoma and expanding activity across solid tumors, providing proof of concept for TCR-T modalities. - Overall, autologous cellular therapies are positioned as an evolving standard in melanoma and a promising approach across solid tumors, with ongoing priorities to improve access, overcome resistance, and optimize combinations.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/42734903/#article-details) ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42734903%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/42734903/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/42734903/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/42734903/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/c24ab723-7c80-48cd-9c68-022ded852586/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/42734903/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/42734903/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/42734903/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42734903%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42734903%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/42734903/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42734903/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42734903/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/42734903/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42734903/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/42734903/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/42734903/#abstract) * [ References ](https://pubmed.ncbi.nlm.nih.gov/42734903/#references) * [ Publication types ](https://pubmed.ncbi.nlm.nih.gov/42734903/#publication-types) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/42734903/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/42734903/#substances) Title & authors Abstract References Publication types MeSH terms Substances Review Cancer Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Cancer%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Cancer%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42734903/) . 2026 Sep 15;132(18):e70612. doi: 10.1002/cncr.70612. # Top advances of the year in autologous cellular therapy in melanoma and solid tumors [Kimberly Loo](https://pubmed.ncbi.nlm.nih.gov/?term=Loo+K&cauthor_id=42734903)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42734903/#full-view-affiliation-1 "Weill Cornell Medicine, New York, New York, USA."), [Allison S Betof](https://pubmed.ncbi.nlm.nih.gov/?term=Betof+AS&cauthor_id=42734903)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42734903/#full-view-affiliation-2 "Stanford University School of Medicine, Stanford, California, USA.") Affiliations Expand ### Affiliations * 1 Weill Cornell Medicine, New York, New York, USA. * 2 Stanford University School of Medicine, Stanford, California, USA. * PMID: **42734903** * DOI: [ 10.1002/cncr.70612 ](https://doi.org/10.1002/cncr.70612) Item in Clipboard Review # Top advances of the year in autologous cellular therapy in melanoma and solid tumors Kimberly Loo et al. Cancer. 2026. Show details Display options Display options Format Abstract PubMed PMID Cancer Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Cancer%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Cancer%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42734903/) . 2026 Sep 15;132(18):e70612. doi: 10.1002/cncr.70612. ### Authors [Kimberly Loo](https://pubmed.ncbi.nlm.nih.gov/?term=Loo+K&cauthor_id=42734903)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42734903/#short-view-affiliation-1 "Weill Cornell Medicine, New York, New York, USA."), [Allison S Betof](https://pubmed.ncbi.nlm.nih.gov/?term=Betof+AS&cauthor_id=42734903)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42734903/#short-view-affiliation-2 "Stanford University School of Medicine, Stanford, California, USA.") ### Affiliations * 1 Weill Cornell Medicine, New York, New York, USA. * 2 Stanford University School of Medicine, Stanford, California, USA. * PMID: **42734903** * DOI: [ 10.1002/cncr.70612 ](https://doi.org/10.1002/cncr.70612) Item in Clipboard Cite Display options Display options Format Abstract PubMed PMID ## Abstract The year 2025 marked significant advances in autologous cellular therapy for melanoma and solid tumors, building on landmark regulatory approvals in 2024. Lifileucel, the first Food and Drug Administration-approved tumor-infiltrating lymphocyte (TIL) therapy for advanced melanoma, demonstrated durable efficacy in the 5-year analysis of the C-144-01 trial, with an objective response rate (ORR) of 31.4% and prolonged responses in a heavily pretreated population. Real world data further supported its effectiveness, with higher ORR likely reflecting earlier lines of therapy and differences in patient selection. Preferentially expressed antigen in melanoma (PRAME)-targeted T-cell receptor (TCR) T-cell therapy (anzu-cel, IMA203) showed promising activity in a phase 1 study, with ORR of approximately 50% in checkpoint inhibitor refractory melanoma, durable responses, and manageable toxicity, validating PRAME as a high value target across multiple tumor types. Next-generation engineered TIL approaches emerged to address limitations of high-dose IL-2. OBX-115, an IL-2 independent TIL platform expressing membrane-bound IL-15 regulated by acetazolamide, demonstrated early clinical activity with ORR of 67% in initial phase 1 data. Additional strategies, including CRISPR-mediated gene editing and checkpoint disruption, highlight a shift toward programmable, self-sustaining cellular therapies. Personalized neoantigen-based therapies advanced with early clinical validation of adoptive T-cell platforms and mRNA vaccines, demonstrating immune activation and improved recurrence-free survival in melanoma. Finally, afamitresgene autoleucel (afami-cel), a MAGE-A4 directed TCR-T therapy, showed durable efficacy in synovial sarcoma and expanding activity across solid tumors, establishing proof of concept for TCR-T approaches. Collectively, these advances position autologous cellular therapy as an evolving standard of care in melanoma and a promising modality across solid tumors, with ongoing efforts focused on improving accessibility, overcoming resistance, and optimizing combinatorial strategies. **Keywords:** cellular therapy; melanoma; solid tumor. © 2026 American Cancer Society. All rights reserved, including rights for text and data mining and training of artificial intelligence technologies or similar technologies. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## References 1. 1. Medina T, Chesney JA, Kluger HM, et al. Long‐term efficacy and safety of lifileucel tumor‐infiltrating lymphocyte cell therapy in patients with advanced melanoma: a 5‐year analysis of the C‐144‐01 study. J Clin Oncol. 2025;43(33):3565‐3572. doi:10.1200/JCO‐25‐00765 2. 1. Karapetyan L, Moser J, Ma BT, et al. Real‐world, evidence‐based, retrospective study of patients infused with commercially released lifileucel for advanced melanoma. Transplant Cell Ther. 2026;32(9):1098‐1110. doi:10.1016/j.jtct.2026.04.044 3. 1. Olson D, Hong Y, Thomas SS, et al. A phase 3 study (TILVANCE‐301) to assess the efficacy and safety of lifileucel, an autologous tumor‐infiltrating lymphocyte cell therapy, in combination with pembrolizumab compared with pembrolizumab alone in patients with untreated unresectable or metastatic melanoma. J Clin Oncol. 2023;41(16 suppl):TPS9607. doi:10.1200/JCO.2023.41.16_suppl.TPS9607 4. 1. Schoenfeld AJ, Lee SM, Doger de Spéville B, et al. Lifileucel, an autologous tumor‐infiltrating lymphocyte monotherapy, in patients with advanced non–small cell lung cancer resistant to immune checkpoint inhibitors. Cancer Discov. 2024;14(8):1389‐1402. doi:10.1158/2159‐8290.CD‐23‐1334 5. 1. Zhang Y, Moore KN, Jazaeri AA, et al. Feasibility of manufacturing and antitumor activity of TIL for advanced endometrial cancers. Int J Mol Sci. 2025;26(15):7151. doi:10.3390/ijms26157151 Show all 60 references ## Publication types * Review Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Review%22%5Bpt%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Review) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42734903/) ## MeSH terms * Antigens, Neoplasm / immunology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antigens%2C+Neoplasm%2Fimmunology%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Antigens%2C+Neoplasm) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42734903/) * Cell- and Tissue-Based Therapy* / methods Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Cell-+and+Tissue-Based+Therapy%2Fmethods%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Cell-+and+Tissue-Based+Therapy) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42734903/) * Humans Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Humans%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Humans) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42734903/) * Immunotherapy, Adoptive* / methods Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Immunotherapy%2C+Adoptive%2Fmethods%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Immunotherapy%2C+Adoptive) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42734903/) * Lymphocytes, Tumor-Infiltrating / immunology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Lymphocytes%2C+Tumor-Infiltrating%2Fimmunology%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Lymphocytes%2C+Tumor-Infiltrating) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42734903/) * Lymphocytes, Tumor-Infiltrating / transplantation Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Lymphocytes%2C+Tumor-Infiltrating%2Ftransplantation%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Lymphocytes%2C+Tumor-Infiltrating) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42734903/) * Melanoma* / immunology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Melanoma%2Fimmunology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Melanoma) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42734903/) * Melanoma* / therapy Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Melanoma%2Ftherapy%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Melanoma) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42734903/) * Neoplasms* / immunology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Neoplasms%2Fimmunology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42734903/) * Neoplasms* / therapy Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Neoplasms%2Ftherapy%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42734903/) ## Substances * Antigens, Neoplasm Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antigens%2C+Neoplasm%22%5Bnm%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=%22Antigens%2C+Neoplasm%22) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42734903/) [x] Cite Copy Download .nbib .nbib Format: AMA APA MLA NLM **Send To** * [Clipboard](https://pubmed.ncbi.nlm.nih.gov/42734903/) * [Email](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42734903%2F%23open-email-panel) * [Save](https://pubmed.ncbi.nlm.nih.gov/42734903/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42734903%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42734903%2F%23open-collections-panel) * [Citation Manager](https://pubmed.ncbi.nlm.nih.gov/42734903/) [x] NCBI Literature Resources [MeSH](https://www.ncbi.nlm.nih.gov/mesh/) [PMC](https://www.ncbi.nlm.nih.gov/pmc/) [Bookshelf](https://www.ncbi.nlm.nih.gov/books) [Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited. Follow NCBI [ Twitter ](https://twitter.com/ncbi) [ Facebook ](https://www.facebook.com/ncbi.nlm) [ LinkedIn ](https://www.linkedin.com/company/ncbinlm) [ GitHub ](https://github.com/ncbi) [ ](https://ncbiinsights.ncbi.nlm.nih.gov/) [Connect with NLM](https://www.nlm.nih.gov/socialmedia/index.html) * [ Twitter ](https://twitter.com/NLM_NIH) * [ SM-Facebook ](https://www.facebook.com/nationallibraryofmedicine) * [ SM-Youtube ](https://www.youtube.com/user/NLMNIH) National Library of Medicine [8600 Rockville Pike Bethesda, MD 20894](https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323) [Web Policies](https://www.nlm.nih.gov/web_policies.html) [FOIA](https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office) [HHS Vulnerability Disclosure](https://www.hhs.gov/vulnerability-disclosure-policy/index.html) [Help](https://support.nlm.nih.gov/?pagename=pubmed%3Apubmed%3Aabstract%3ANONE) [Accessibility](https://www.nlm.nih.gov/accessibility.html) [Careers](https://www.nlm.nih.gov/careers/careers.html) * [NLM](https://www.nlm.nih.gov/) * [NIH](https://www.nih.gov/) * [HHS](https://www.hhs.gov/) * [USA.gov](https://www.usa.gov/)
## Related Clinical Research

- [Immune-pressure redistribution as a framework for resistance to PD-1/PD-L1 blockade](https://medichelpline.com/clinical-feed/pubmed-42763389.md) (DOI: 10.1186/s12943-026-02786-4)
- [Challenging FDA-Approved Cancer Drug Dosages: A Patient and Research Perspective](https://medichelpline.com/clinical-feed/kff-health-news-2-how-much-of-a-cancer-drug-is-too-much-patients-researchers-challenge-fda.md)
- [Source page lacked article content for immune checkpoint inhibitor strategies in lung cancer](https://medichelpline.com/clinical-feed/frontiers-in-immunology-16-immune-checkpoint-inhibitor-based-combinatory-and-alternative-strategies-for.md)
- [CT-guided intratumoral immunotherapy for advanced solid tumors: safety and systemic effects](https://medichelpline.com/clinical-feed/frontiers-in-immunology-3-ct-guided-intratumoral-immunotherapy-for-advanced-solid-tumors-a-prospective.md)
- [KEYNOTE-942 5-Year Update: Intismeran Autogene Plus Pembrolizumab vs Pembrolizumab in High‑Risk Re](https://medichelpline.com/clinical-feed/pubmed-42223134.md) (DOI: 10.1200/JCO-26-00835)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.